These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 2033478)

  • 21. [Erythropoietin: from established therapeutic procedures in renal anemia to future areas of use].
    Marsen TA; Pollok M; Baldamus CA
    Med Klin (Munich); 1992 Apr; 87(4):207-14. PubMed ID: 1579099
    [No Abstract]   [Full Text] [Related]  

  • 22. [Recombinant human erythropoietin: 18 months of continuous use in substitution hemodialysis].
    Canaud B; Polito-Bouloux C; Rivory JP; Donnadieu P; Taib J; Florence P; Mion C
    Nephrologie; 1990; 11(1):5-10. PubMed ID: 2374643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost of treating predialysis patients with recombinant human erythropoietin.
    Durand-Zaleski I; Goldfarb B; Blum-Boisgard C; Drüeke T; Kreis H
    Nephrol Dial Transplant; 1993; 8(4):311-4. PubMed ID: 8390004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Utilization of erythropoietin in the treatment of the anemia due to chronic renal failure.
    Drüeke T; Zins B; Naret C; Casadevall N; Goureau Y; Bererhi L; Peterlongo F; Castaigne JP; Zingraff J; Delons S
    Adv Nephrol Necker Hosp; 1989; 18():187-206. PubMed ID: 2493715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Erythropoietin.
    Beresford CH
    N Z Med J; 1989 Apr; 102(866):185-6. PubMed ID: 2652007
    [No Abstract]   [Full Text] [Related]  

  • 26. [Recombinant human erythropoietin in the treatment of the anemia of multiple myeloma with kidney failure].
    Arenas Gracia M; Abad Gosálvez A; Colomina Avilés J; Pascual Pérez R; Ferriz Moreno P
    An Med Interna; 1995 Apr; 12(4):187-8. PubMed ID: 7620064
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Erythropoietin and transfusions in patients with anemia of chronic renal failure origin : an update view].
    Duclos J; Olea C; Aguirre H; Alvarez MC; Salgado MC
    Rev Med Chil; 1995 Apr; 123(4):451-5. PubMed ID: 8525189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of anemia in chronically dialyzed patients].
    Moynot A
    Nephrologie; 1998; 19(3):125-7. PubMed ID: 9633055
    [No Abstract]   [Full Text] [Related]  

  • 29. Management of blood pressure changes during recombinant human erythropoietin therapy.
    Levin N
    Semin Nephrol; 1989 Mar; 9(1 Suppl 2):16-20. PubMed ID: 2669081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adverse effects of therapy for the correction of anemia in hemodialysis patients.
    Watson AJ
    Semin Nephrol; 1989 Mar; 9(1 Suppl 1):30-4. PubMed ID: 2648519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erythropoietin.
    Haberl M
    Aust Nurses J; 1990 Sep; 20(2):29. PubMed ID: 2268202
    [No Abstract]   [Full Text] [Related]  

  • 32. The clinical effects of recombinant human erythropoietin for the treatment of anemia in end stage renal disease patients on dialysis.
    Uthayanaka Y; Jirajan B; Krairithichai U; Jantavanich N
    Southeast Asian J Trop Med Public Health; 1993 Sep; 24(3):577-82. PubMed ID: 8160072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Single weekly dose of recombinant erythropoietin in children with chronic renal insufficiency].
    Guízar JM; Gutiérrez MJ; Sánchez G; Kornhauser C
    Rev Invest Clin; 1996; 48(3):173-7. PubMed ID: 8966377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Is the index of response to erythropoietin (IRE) a good marker of adequate dialysis?].
    Pérez-García R; Rodríguez-Benítez P; Villaverde MT; Valderrábano F
    Nefrologia; 2001; 21(6):606-7. PubMed ID: 11881433
    [No Abstract]   [Full Text] [Related]  

  • 35. Efficacy and tolerability of intravenous continuous erythropoietin receptor activator: a 19-week, phase II, multicenter, randomized, open-label, dose-finding study with a 12-month extension phase in patients with chronic renal disease.
    Besarab A; Salifu MO; Lunde NM; Bansal V; Fishbane S; Dougherty FC; Beyer U;
    Clin Ther; 2007 Apr; 29(4):626-39. PubMed ID: 17617286
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A multicenter trial of Recormon within the framework of international controlled research].
    Tareeva IE; Nikolaev AIu; Klepikov PV; Lashutin SV; Riabov SI; Shostka GD; Ermolenko VM; Rozental' RL; Vorob'ev PA; Miagkov AV
    Ter Arkh; 1992; 64(8):59-62. PubMed ID: 1440400
    [No Abstract]   [Full Text] [Related]  

  • 37. Response to recombinant human erythropoietin (r-Hu EPO) and L-carnitine combination in patients with anemia of end-stage renal disease.
    Boran M; Dalva I; Gönenç F; Cetin S
    Nephron; 1996; 73(2):314-5. PubMed ID: 8773364
    [No Abstract]   [Full Text] [Related]  

  • 38. Full results on risks of epoetin emerge 14 years after major dialysis study.
    Epstein K
    BMJ; 2012 May; 344():e3535. PubMed ID: 22619221
    [No Abstract]   [Full Text] [Related]  

  • 39. Dose escalation induces tolerance to side-effects of erythropoietin in a patient with dialysis anaemia: case report.
    Ohira N; Takasugi K; Takasugi N; Yorioka N; Ito T; Kushihata S; Takemasa A
    J Int Med Res; 1998; 26(2):102-5. PubMed ID: 9602990
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The ESA saga: a perfect storm of failed expectations and over-regulation.
    Wish J
    Nephrol News Issues; 2011 Aug; 25(9):13-4. PubMed ID: 21905525
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.